See more : XPAC Acquisition Corp. (XPAXU) Income Statement Analysis – Financial Results
Complete financial analysis of Connect Biopharma Holdings Limited (CNTB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Connect Biopharma Holdings Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Ecograf Ltd (ECGFF) Income Statement Analysis – Financial Results
- G Mining Ventures Corp. (GMIN.TO) Income Statement Analysis – Financial Results
- Pushpay Holdings Limited (PHPYF) Income Statement Analysis – Financial Results
- T.C.J. Asia Public Company Limited (TCJ.BK) Income Statement Analysis – Financial Results
- Solis Minerals Ltd. (SLMN.V) Income Statement Analysis – Financial Results
Connect Biopharma Holdings Limited (CNTB)
About Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 988.00K | 1.03M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -988.00K | -1.03M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 51.91M | 95.26M | 81.34M | 23.12M | 15.44M |
| General & Administrative | 14.52K | 20.37M | 19.23M | 7.31M | 1.41M |
| Selling & Marketing | 13.51M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.53M | 20.37M | 19.23M | 7.31M | 1.41M |
| Other Expenses | -4.35M | -940.31K | -2.98M | -1.07M | -411.44K |
| Operating Expenses | 62.07M | 114.69M | 97.59M | 29.36M | 16.44M |
| Cost & Expenses | 62.07M | 114.69M | 97.59M | 29.36M | 16.44M |
| Interest Income | 5.20K | 1.56M | 97.67K | 109.84K | 154.65K |
| Interest Expense | 0.00 | 21.03K | 6.91K | 6.43K | 7.69K |
| Depreciation & Amortization | 988.00K | 1.01M | 640.98K | 221.05K | 114.61K |
| EBITDA | -58.37M | -111.31M | -204.93M | -118.21M | -24.78M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -62.07M | -117.66M | -99.15M | -30.30M | -15.99M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.69M | -403.66K | -103.21M | -89.07M | -8.41M |
| Income Before Tax | -59.38M | -116.12M | -204.94M | -119.37M | -24.46M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 120.00K | 297.52K | 266.47K | 934.46K | -442.49K |
| Net Income | -59.50M | -116.42M | -205.21M | -120.30M | -24.02M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.08 | -14.50 | -25.00 | -14.45 | -3.02 |
| EPS Diluted | -1.08 | -14.50 | -25.00 | -14.45 | -3.02 |
| Weighted Avg Shares Out | 55.07M | 55.04M | 52.27M | 53.94M | 55.82M |
| Weighted Avg Shares Out (Dil) | 55.07M | 55.04M | 52.27M | 53.94M | 55.82M |
Connect Biopharma's Latest Dermatitis Drug Update Fails to Pump Up Shares
Amberstone Biosciences Secures $12 Million Series A Financing to Advance Immuno-Oncology Pipeline of Tumor Microenvironment Activated Therapeutics
Connect Biopharma's Mid-Stage Atopic Dermatitis Trial Meets Primary Endpoint
Connect Biopharma to Participate at Upcoming Conferences
Connect Biopharma to Participate at the Jefferies Virtual China Biotech Summit
Connect Biopharma Provides Business Update and Reports First Half 2021 Financial Results
Connect Biopharma to Host First Half 2021 Financial Results Conference Call on September 1, 2021
Connect Biopharma Hires General Counsel & Chief Compliance Officer and Appoints a New Board Member
Connect Biopharma to Participate at the Jefferies Virtual Healthcare Conference
Connect Biopharma Announces First Subject Dosed in Phase I Trial Evaluating Safety, Tolerability and Pharmacokinetic Profile of CBP-174 in Healthy Adult Subjects
Source: https://incomestatements.info
Category: Stock Reports